Show
Sort by
-
NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951
-
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report
-
Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951
-
HOX11L2 expression linked to t(5;14)(q35;q32) is not associated with poor prognosis in childhood T-ALL treated in EORTC trials 58 881 and 58 951
-
Treatment outcome in infant acute lymphoblastic leukemia.
-
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 Randomized Phase III Trial.
-
Long-term results of three randomized trials (58831,58832,58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report.
-
Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors : results of the EORTC Children Leukemia Cooperative Study 58872
-
Systemic Effect of Intrahepatic Methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 1997, 15: 1824-1830.